S. Murray Sherman to Anilides
This is a "connection" page, showing publications S. Murray Sherman has written about Anilides.
Connection Strength
0.270
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 03; 34(3):347-359.
Score: 0.199
-
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022 12 15; 128(24):4203-4212.
Score: 0.045
-
Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
Score: 0.026